Breaking News

Model Medicines Reports Positive Results for Anti-COVID-19 Drug Candidate

Based on the findings, the oral drug candidate MDL-001 has been accepted into NIH's Antiviral Program for Pandemics.

Author Image

By: Charlie Sternberg

Associate Editor

Model Medicines, a pharmatech company working to transform the drug discovery and development industry and accelerate the creation of life-changing drugs using artificial intelligence (AI) and machine learning (ML), has announced preclinical results demonstrating once daily, oral dosing of MDL-001 significantly reduces the viral load of SARS-CoV-2 in the lungs of an established mouse-adapted animal model of SARS-CoV-2 infection (two-way ANOVA, P < 0.01).   The company previously reported da...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters